Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.52 |
| ▸ | HMGCR | P04035 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PDE6D | O43924 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL17967550 | 0.93 | AKT1 (0.49) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| Bromide SCHEMBL4600624 | 0.93 | AKT1 (0.53) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL3445256 | 0.85 | HMGCR (0.56) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| Bromide SCHEMBL21001081 | 0.84 | HMGCR (0.52) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL29086516 | 0.83 | AKT1 (0.55) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL29482554 | 0.82 | HMGCR (0.58) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL28494229 | 0.82 | HMGCR (0.56) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL4914199 | 0.82 | HMGCR (0.56) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL28860507 | 0.82 | HMGCR (0.56) | AKT1HMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL2690 | 0.82 | HMGCR (0.58) | AKT1HMGCRALDH1A1CYP3A4PDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114280181-B | Rosuvastatin intermediate and detection method of related substances thereof | 浙江海翔川南药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114280181-A | Detection method of rosuvastatin intermediate and related substances thereof | 浙江海翔川南药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-111170950-A | Method for preparing rosuvastatin calcium salt | 河南豫辰药业股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-9376397-B2 | Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-28 | — | — | US | disclosed |
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-21 | — | — | US | disclosed |
| EP-2391609-B1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2015-01-28 | — | — | EP | disclosed |
| EP-2341054-B1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS (SI) | 2014-06-25 | — | — | EP | disclosed |
| EP-2351762-B1 | NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE | KANEKA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8455640-B2 | Process for statins and its pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| EP-1937696-B1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS (SI) | 2013-05-22 | — | — | EP | disclosed |
| US-8404841-B2 | Process for the preparation of statins and their pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | disclosed |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-01-26 | — | — | US | disclosed |
| EP-2351762-A1 | NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE | Kaneka Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2341054-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals d.d. (SI) | 2011-07-06 | — | — | EP | disclosed |
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | MSN LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | AKT1 163/4885HMGCR 1/4885ALDH1A1 2068/4885 |
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | HMGCR, PCSK9, NPC1L1 | AKT1 1176/4885HMGCR 1/4885ALDH1A1 1715/4885 |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | HMGCR, NPC1L1, PCSK9 | AKT1 1563/4885HMGCR 1/4885ALDH1A1 1466/4885 |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | HMGCR, COASY, LSS | AKT1 661/4885HMGCR 1/4885ALDH1A1 889/4885 |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | AKT1 163/4885HMGCR 1/4885ALDH1A1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.